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Introduction: Insulin allergy to human insulin preparations during the treatment of diabetes is suggested to occur
at rates ranging from <1.0% to 2.4%. These reactions vary from mild localized reactions, which resolve with
repeated exposure, to life-threatening anaphylaxis and death. The management of persistent insulin allergy in type
1 diabetes mellitus is particularly complicated because ongoing treatment with insulin is essential.
Case presentation: We present the case of a 12-year-old Caucasian girl with localized allergy to the insulin
excipient metacresol, and the subsequent desensitization therapy using continuous subcutaneous insulin infusion
with simultaneous intravenous insulin infusion.
Conclusions: This is the first documented case of allergy to the metacresol component of insulin in the pediatric
type 1 diabetes literature. We describe an approach to diagnosis and management of metacresol allergy in type 1
diabetes.Introduction
Insulin allergy, although less common since the intro-
duction of human insulin [1], is still an issue in the ma-
nagement of diabetes. Suggested rates of insulin allergy
range from <1% to 2.4% [1,2], covering the spectrum
from mild localized reactions, which resolve with re-
peated exposure [3], to life-threatening anaphylaxis or
death [4]. The management of persistent insulin allergy
in type 1 diabetes mellitus (T1DM) is particularly com-
plicated because ongoing treatment with insulin is es-
sential. Commercially available insulin contains multiple
ingredients: the insulin molecule itself in a variety of
forms; and a range of additives, preservatives and buf-
fers, commonly referred to as excipients [5]. Narrowing
down the specific cause of the allergy is therefore not
simple. In the past, this has been aided by the commer-
cial availability of insulin allergy test kits [5-7], however,
manufacture of these has recently ceased. We present a
case of allergic reaction to the insulin excipient metacresol* Correspondence: ben.wheeler@otago.ac.nz
1Department of Women’s and Children’s Health, University of Otago,
Dunedin 9054, New Zealand
2Edgar National Centre for Diabetes and Obesity Research, University of
Otago, Dunedin 9054, New Zealand
© 2012 Wheeler and Taylor; licensee BioMed C
Creative Commons Attribution License (http:/
distribution, and reproduction in any mediumin a child with T1DM, and describe a diagnostic approach
and management.Case presentation
A 12-year-old Caucasian girl with newly diagnosed T1DM
was commenced on twice-daily basal ProtaphaneW and
bolus insulin aspart with meals. Within the first week
of treatment she complained of increasing pain with
ProtaphaneW injections. By Week 2, this had progressed
to include additional localized erythema. Humulin neutral
protamine Hagedorn (NPH)W was substituted, with some
benefit but her symptoms persisted. Glargine and detemir
insulins were then trialed but localized symptoms were
worse. Past history revealed a localized erythema to some
soap and adhesive preparations. At 6 weeks from diabetes
diagnosis, her aspart injections also began to cause pain
and localized erythema. This progressed over a few weeks
to include localized skin breakdown occurring within 5
minutes of injection (Figure 1) that left her with multiple
healing abrasions (Figure 2). The pain and distress were
such that glycemic control was impaired because of injec-
tion avoidance. Antihistamines (loratidine and cetirizine)
resulted in some reduction in her Humulin NPHW-related
symptoms, but with no effect on those of aspart.entral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Figure 1 Immediate localized skin breakdown.
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testing with latex, and following injections of 0.9% saline
with a variety of skin preparations and needle types.
Initial blood work revealed negative results for spe-
cific immunoglobulin E (IgE) to: human insulin, porcine
insulin, bovine insulin, and latex. Eosinophils were 0.2
(reference range <0.9). Total IgE was raised at 112kU/L
(reference range <100).
Next, subcutaneous testing was conducted on all avai-
lable insulin preparations (ProtaphaneW, ActrapidW, lispro,
aspart, glulisine, glargine, Humulin NPHW, Humulin RW,
detemir). All elicited positive responses: pain followed by
localized erythema, urticaria, and eventual rapid skin
breakdown. An allergic reaction to human insulin seemed
less probable because the human insulin molecule dif-
fers between preparations. To explore this fully, Novo
NordiskW diluting medium, which does not containFigure 2 Multiple healing abrasions.insulin but does have similar excipients to insulin aspart,
was the next step. The subcutaneous test with Novo
NordiskW diluting medium elicited a similar positive
reaction.
Because the patient had an allergic reaction to all
available insulin, a review of insulin preparations and ex-
cipients was conducted as described by Heinzerling
et al. [5]. Metacresol was the only excipient common to
all but it was not available commercially for testing.
However, on review we discovered that the only signifi-
cant ingredient in Lilly™ ‘saline’ penfills was metacresol.
Subcutaneous testing again elicited an identical positive
reaction. Thus metacresol was the only agent common
to all positive tests. Based on this finding, a presumed al-
lergy to the excipient metacresol was diagnosed.
Desensitization therapy was commenced 6 weeks from
first presentation using insulin aspart via continuous sub-
cutaneous insulin infusion (CSII). Intravenous ActrapidW
via a peripherally-located central catheter was used to
maintain normoglycemia and prevent ketosis. This was
well tolerated at infusion rates ≤3 units/hour. Rates above
this resulted in central chest discomfort. CSII was com-
menced at a rate of 0.025 units/hour with a plan to in-
crease the infusion rate by 0.05 units every 6 hours. If the
patient felt minor discomfort, then the rate would remain
unchanged, but if she had significant pain or urticaria the
rate was to be reduced by 0.05 units/hour. Within 2 hours
of commencement the infusion was stopped due to imme-
diate localized urticaria followed by substantial pain. At
this stage, 3 days of oral prednisone 20mg was added. On
Day 2, a tenfold dilution with 0.9% saline was used to re-
duce the starting dose of aspart to 0.0025 units/hour. A
pump rate of 0.25 units/hour was reached without inci-
dent, and a twofold aspart dilution was substituted at a
new pump rate of 0.05 units/hour (0.025 units/hour
aspart). When a pump rate of 0.3 units/hour was tole-
rated, undiluted aspart was substituted and commenced at
0.15 units/hour. The estimated full basal rate of 0.35
units/hour was successfully achieved by 120 hours. At this
point, meal boluses were added, initially with a slow wave
meal bolus over 4 hours. This was replaced at 156 hours
with a dual-wave bolus (50% immediate, 50% over 2
hours). By 168 hours, small (<3.5 units) standard boluses
of aspart were tolerated without discomfort, increasing to
6.5 units by 312 hours.
Discussion
We describe the first documented case of an allergic re-
action to the metacresol component of insulin in the
pediatric T1DM literature. Allergy to the metacresol in
insulin has been described previously in an adult with
T1DM [8]. Because metacresol is universally present in
all current insulin preparations, we believe it has been
overlooked as a possible cause of insulin allergy in some
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in our case erythema, urticaria, pain, and excoriation with
abrasion and/or epidermal separation within 5 minutes of
injection, is unusual and not previously described. It is
probable that the skin reaction represents a mixed allergic
response with Type I and IV allergy components. The
wider literature on metacresol describes burn and skin
breakdown reactions with cutaneous exposure [9], which
may help explain this phenomenon. Metacresol is present
in a variety of common products ranging from soaps to
adhesives, agents to which our patient had experienced
mild reactions in the past. A dose-response relationship
was also observed: the lowest reaction was seen with
Humulin NPHW (metacresol 1.6mg/mL) and the most
severe reactions were seen with lispro and glulisine
(metacresol 3.15mg/mL).
In the past, the diagnosis of insulin allergy was facili-
tated by commercially available insulin allergy test kits
[5]. These kits contained all the potential ingredients of
commercial insulin preparations including several types
of insulin and a range of excipients that included preserva-
tives (e.g. metacresol), retardants (e.g. protamine sulfate),
stabilizers (e.g. zinc), acid and base buffers, and isotonic
agents (e.g. glycerol). Recently, manufacture of these kits
has ceased with the current literature not responding to
this change in circumstance.
We describe a novel approach to this dilemma. Com-
mon preparations are available that can be used via sub-
cutaneous testing, in conjunction with blood tests, to
isolate a specific cause of insulin allergy after excluding
other common causes, for example injection technique,
reaction to latex, skin preparations or needle types. The
procedures to start a specific investigation are twofold:
blood tests, including total IgE and specific IgE to
human, porcine and bovine insulin as well as latex; and
subcutaneous testing of all available insulin preparations.
The taking of antihistamines during the testing and
three days prior to testing is to be avoided. Because the
active ingredient (insulin) and some excipients do differ
between preparations, the pattern of reaction might sug-
gest the cause. Next, Novo Nordisk™ diluting fluid can
be helpful to distinguish an excipient allergy from true
insulin and/or aspart allergy. Because the Novo Nordisk™
diluting fluid does not contain insulin but does have
similar excipients to insulin aspart, a negative result
would strongly suggest an allergic reaction to aspart and
not to an excipient, whereas a positive result would indi-
cate an excipient allergy. Investigating metacresol, the
preservative universally present in available commercial
insulin, is the next step. Lilly™ ‘saline’ for practice pen in-
jection contains metacresol as the only ingredient other
than sodium chloride, water for injection, and acid/base
buffers. A positive reaction to subcutaneous testing with
Lilly™ ‘saline’ strongly suggests metacresol allergy.If diagnosed, options for treatment of non-spontaneously
resolving metacresol allergy are few. Past insulin prepa-
rations did not contain metacresol, for example some
porcine insulins, MonotardW, and UltratardW. However,
metacresol is present as a preservative in all currently
available insulin, making a desensitization approach essen-
tial. Traditionally, successive subcutaneous injections of
increasingly less dilute preparations of insulin are given
[5]. More recently, SCII has been used with success. In
previous case reports, [6,10] a low basal rate of between
0.1 units/hour and 0.3 units/hour has been successful at
initiating desensitization; however, as we describe, sub-
stantially lower concentrations or even dilution with ste-
rile saline may be required.
The time required for successful desensitization varies,
and is patient and technique specific. If titration proves
slow, then ketoacidosis from insulin deficiency quickly
results. Intravenous insulin as previously described [10,11]
can provide an avenue for temporary insulin replacement
during desensitization. Why intravenous therapy as op-
posed to subcutaneous therapy is generally well tolerated
is not fully understood. Suggested mechanisms range from
the simple mechanics of putting small volumes of insulin
into a large central vein with subsequent rapid distribution
(particularly relevant for localized reactions) through to
differences in the immune system response depending on
the route of insulin administration [11]. Complications
can still occur, with transient urticaria documented [10]
along with the novel central chest pain seen in our
patient.
Systemic treatment with oral antihistamine and/or
steroid has been used [12]. We found twice-daily oral
antihistamine provided minimal improvement. Oral ste-
roids possibly provided some benefit during our desen-
sitization therapy, but are not ideal as a long-term option.
Our patient continues on an antihistamine, but for subse-
quent local flare-ups we have had success using soluble
hydrocortisone 0.1mL (50mg/mL) added to 1.9mL aspart
insulin in the pump reservoir, to provide low-level local
immune suppression.Conclusions
In this report we document the first case of allergy to
metacresol in the pediatric diabetes literature; metacre-
sol is an excipient common to all currently available in-
sulin preparations. To the best of our knowledge this is
also the first documented case of metacresol allergy suc-
cessfully treated with desensitization therapy. A novel
and simple method of exploring the etiology of insulin
allergy is described using readily available preparations.
Although far from ideal, this method can allow the
causative agent to be distinguished: whether this is human
insulin, or an excipient.
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